总结COVID-19与未来诊断炎症性风湿及肌肉骨骼疾病关联的证据:一项快速综述
该快速综述系统检索截至2022年8月的文献,纳入80项研究(69例病例报告、10项病例系列和1项横断面研究),评估急性COVID-19与后续炎症性风湿肌肉骨骼疾病(iRMD)诊断的关联。纳入研究报告的iRMD以「反应性关节病」(47例)、「未特指的炎症性关节病」(18例)、类风湿关节炎(12例)和系统性红斑狼疮(11例)常见,从COVID-19诊断到iRMD表现的时间为0至120天。作者认为纳入研究的证据水平低、质量普遍较差,需要前瞻性观察性研究来确认关联及iRMD在人群层面的可能影响。
要点
- 纳入80项研究(69例病例报告、10项病例系列、1项横断面研究),证据水平低且质量普遍较差。
- 常见iRMD为反应性关节病(47例)、未特指炎症性关节病(18例)、类风湿关节炎(12例)和系统性红斑狼疮(11例)。
- 横断面研究报告37%的COVID-19患者发生「COVID后关节炎」,诊断至iRMD表现时间为0至120天。
核心结论
- 作者认为纳入研究的证据水平低且质量普遍较差。
- 作者提出需要前瞻性观察性研究来确认关联及COVID-19后iRMD在人群层面的可能影响。
研究设计与样本
- 快速综述,系统检索Medline、EMBASE和两个COVID-19数据库,截至2022年8月。
- 纳入报告COVID-19后发生iRMD的病例研究、病例系列、横断面研究、病例对照研究和队列研究。
- 由一名评审者进行标题和摘要筛选,两名评审者进行全文筛选;一名评审者提取数据和质量评价,第二人核实。
- 使用研究类型特定的批判性评价工具。
- 共纳入80项研究:69例病例报告、10项病例系列和1项横断面研究。
主要发现
- 常见报告的iRMD为「反应性关节病」(n=47)、「未特指的炎症性关节病」(n=18)、类风湿关节炎(n=12)和系统性红斑狼疮(n=11)。
- 横断面研究报告37%的COVID-19患者发生「COVID后关节炎」。
- 从COVID-19诊断到iRMD表现的时间范围为0至120天。
- 提出的机制包括自身免疫过程、异常炎症反应、关节间隙定植、严重急性呼吸综合征冠状病毒2直接损伤和遗传易感性。
关键数值与推荐
- 横断面研究报告37%的COVID-19患者发生「COVID后关节炎」。
- 从COVID-19诊断到iRMD表现的时间范围为0至120天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出纳入研究的证据水平低且质量普遍较差。
- 作者提出需要前瞻性观察性研究来确认关联及COVID-19后iRMD在人群层面的可能影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Musculoskeletal symptoms are commonly reported following acute COVID-19. It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seeks to identify evidence for an association between acute COVID-19 and subsequent iRMD diagnosis. METHODS: A rapid review of the literature using a systematic search of Medline, EMBASE and two COVID-19 databases was undertaken until August 2022. Case studies, case series, cross-sectional, case-control, and cohort studies reporting patients with an incident iRMD following COVID-19 were included. Title and abstract screening were conducted by one reviewer and full text screening by two reviewers. Data extraction and quality appraisal were by one reviewer, with a second verifying. Study-type specific critical appraisal tools were used. RESULTS: Results were narratively synthesized. A total of 80 studies were included (69 case reports, 10 case series and 1 cross-sectional study). Commonly reported iRMDs were "reactive arthropathies" (n = 47), "inflammatory arthropathies unspecified" (n = 18), rheumatoid arthritis (n = 12) and systemic lupus erythematosus (n = 11). The cross-sectional study reported 37% of those with COVID-19 developed "post COVID arthritis." Time from diagnosis of COVID-19 to iRMD presentation ranged from 0 to 120 days. Several mechanisms were proposed to explain the association between COVID-19 and iRMD development: autoimmune processes, aberrant inflammatory responses, colonization of joint spaces, direct damage from the severe acute respiratory syndrome coronavirus 2 virus and genetic predisposition. CONCLUSION: The level of evidence of the studies included in this review was low and the quality generally poor. Prospective observational studies are required to confirm associations and likely impact of post COVID-19 iRMDs at a population level.
引用
- Mudge HR, Honey JR, Tachoukaft S, et al. Summarizing Evidence of Associations of COVID-19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review. Arthritis Care Res (Hoboken). 2023. PMID: 37691274. doi:10.1002/acr.25227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。